+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Opioid Narcotics Market by Route of Administration (Injectable, Nasal, Oral), Product Type (Branded, Generic), Molecule Type, Formulation Type, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6142780
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The landscape of opioid narcotics is shaped by a complex interplay of therapeutic necessity and public health concern. The persistent prevalence of chronic and acute pain management challenges has driven continued reliance on opioid-based analgesics, while intensifying scrutiny over potential abuse has heightened regulatory oversight. Against this backdrop, pharmaceutical innovators and healthcare providers must reconcile the demand for effective pain relief with stringent controls designed to curb misuse. This tension underscores the critical need for a nuanced view of industry dynamics.

In recent years, policymakers, clinicians, and patient advocacy groups have exerted increasing influence on prescribing practices. Stricter guidelines and enhanced monitoring programs aim to prevent diversion and addiction, yet they also introduce operational complexities for manufacturers and distributors. Meanwhile, emerging science has enabled the formulation of advanced delivery systems and abuse-deterrent technologies. These developments offer both promise and challenge, compelling stakeholders to balance innovation with responsibility in a highly regulated environment.

As the regulatory landscape evolves, market participants must anticipate shifting priorities across safety, efficacy, and accessibility. Collaboration among drug developers, governmental agencies, and care providers is crucial to align objectives and mitigate unintended consequences. This introduction sets the stage for a deeper examination of the forces redefining the opioid narcotics sector, offering strategic insights to guide decision-makers as they navigate this multifaceted domain.

Examining the Profound Transformative Shifts Redefining Opioid Narcotics Development Commercialization and Regulatory Oversight in a Dynamic Healthcare Environment

The opioid narcotics sector has witnessed transformative shifts driven by advancements in drug discovery and the integration of cutting-edge technologies. Novel analgesic compounds are being engineered to enhance receptor selectivity and minimize dependency potential. Simultaneously, the rise of digital health platforms has enabled remote monitoring of patient adherence, offering real-time insights into usage patterns. These developments are fundamentally changing how therapies are evaluated, prescribed, and consumed, ushering in an era of data-informed pain management.

On the commercialization front, partnerships between pharmaceutical companies and technology providers are accelerating the deployment of abuse-deterrent formulations and smart delivery systems. Incorporating sensors into transdermal patches and connected inhalers allows for precise dosing while flagging irregular usage. Regulators have responded with adaptive frameworks that incentivize safer product designs, providing expedited pathways for candidates that demonstrate reduced risk profiles. Such policy shifts reflect a growing emphasis on patient safety without stifling innovation.

Moreover, the shift toward patient-centric care is redefining clinical trial methodologies and post-market surveillance. Real-world evidence is increasingly leveraged to refine dosing guidelines and identify at-risk populations. Telemedicine initiatives are expanding access in underserved regions, challenging established distribution models. Emerging concepts in regulatory science, such as adaptive trial designs and remote data capture, are further reducing development timelines while maintaining rigorous safety standards. As these paradigm changes converge, industry stakeholders must remain agile, aligning research priorities and operational strategies with emerging best practices to sustain competitiveness in a rapidly evolving environment.

Analyzing the Cumulative Impact of New United States Tariffs Enacted in 2025 on the Opioid Narcotics Supply Chain Cost Structures and Market Access

The introduction of new tariffs on imported opioid precursors and API components has created ripple effects throughout the supply chain. Manufacturers that historically relied on overseas sourcing for key intermediates are now reassessing procurement strategies, evaluating domestic alternatives, and negotiating with suppliers to mitigate rising costs. In turn, production facilities must adapt to shifting input prices, recalibrating operational budgets and revising distribution agreements in response to evolving trade policies.

Cost pressures extend beyond raw materials, as logistics providers adjust freight rates to account for increased customs duties. These added expenses influence pricing negotiations with healthcare providers and payers, potentially altering formulary considerations. At the same time, some companies are exploring vertical integration opportunities to secure a more resilient pipeline of essential ingredients, balancing investment in local manufacturing capacity against the capital requirements associated with facility expansion and regulatory compliance.

Market access challenges have emerged in parallel, as tariffs complicate cross-border collaborations and licensing agreements. Entities engaged in global clinical trials must contend with variable duty structures, affecting trial budgets and timelines. While the long-term goal of encouraging domestic production may enhance supply reliability, stakeholders must navigate transitional complexities. Stakeholders are also exploring collaborative platforms to share best practices and harmonize compliance activities, fostering a collective response to cross-border trade challenges.

Key Segmentation Insights Revealing How Route Of Administration Product Type Molecule Type Formulation And Distribution Channel Influence Opioid Narcotics

Analysis of opioid narcotics by their route of administration distinguishes between injectable therapies delivered intravenously or intramuscularly, nasal sprays offering rapid mucosal absorption, oral tablets designed for systemic distribution, rectal suppositories providing alternative localized action, and transdermal systems that facilitate controlled release through the skin. Each modality presents unique considerations for onset time, patient compliance, and clinical setting, prompting manufacturers to tailor formulations and support programs accordingly.

Delving into product type reveals the dynamic interplay between branded innovations and generic equivalents. Branded narcotics often incorporate proprietary delivery technologies or abuse-deterrent features that command premium pricing and enhance differentiation. Generic entrants, by contrast, leverage established molecular profiles to drive cost efficiencies and expand access. Navigating patent cliffs and regulatory exclusivity periods requires careful alignment of product pipelines with market timing to sustain revenue streams over the product lifecycle.

A molecule type perspective underscores the varied pharmacological attributes of fentanyl, hydrocodone, morphine, and oxycodone, each with distinct potency levels and risk profiles. The choice between extended release formulations and immediate release versions further influences prescribing patterns, with slower-acting options favored for chronic pain management and rapid analgesics reserved for acute pain episodes. Distribution channels span hospital pharmacy networks, online pharmacy platforms, and retail pharmacy outlets, shaping reach and usage monitoring. Finally, the end user landscape encompasses ambulatory care settings where pain management protocols differ from those in home healthcare or hospital environments, driving nuanced demand signals across care contexts. By synthesizing these segmentation dimensions, organizations can craft nuanced market approaches that align product attributes with patient needs and regulatory requirements.

Strategic Regional Insights Highlighting Variations And Growth Drivers Across the Americas Europe Middle East And Africa and Asia Pacific Markets

In the Americas, opioid narcotics markets are characterized by mature healthcare systems and well-established regulatory frameworks. Prescribing practices in North America continue to balance clinical necessity with heightened vigilance following historical trends in misuse. In Latin America, evolving policy environments and expanding healthcare coverage are creating new opportunities for patient access, although infrastructure disparities and supply chain constraints require targeted distribution strategies.

Within Europe, Middle East and Africa, regulatory harmonization efforts across the European Union contrast with diverse control mechanisms in Middle Eastern and African nations. European markets emphasize stringent risk evaluation processes and robust pharmacovigilance, while emerging markets in the Middle East and Africa are investing in expanding healthcare infrastructure to address unmet pain management needs. Stakeholders must adapt to regional reimbursement models and navigate varying import regulations to ensure continuity of supply.

Asia Pacific presents a heterogeneous mix of advanced economies and developing regions. In countries with aging populations, demand for controlled release opioid formulations is rising alongside initiatives to improve palliative care. Conversely, in certain emerging markets, regulatory caution and limited manufacturing capabilities have slowed market growth, prompting collaborations between global pharmaceutical firms and local players. Tailored market entry strategies that account for diverse regulatory pathways and cultural attitudes toward opioid use are essential in this dynamic region. Understanding these regional nuances enables tailored engagement strategies that address local pain management frameworks and cultural considerations.

Key Companies Insights Examining Leading Pharmaceutical Players Innovations Strategic Partnerships And Competitive Differentiators in Opioid Narcotics

Leading pharmaceutical companies have intensified research into abuse-deterrent technologies, leveraging partnerships with specialty biotech firms to co-develop advanced formulations. Strategic alliances with device manufacturers have yielded integrated delivery solutions, such as sensor-equipped transdermal systems, that offer real-time adherence monitoring and data analytics capabilities. By combining proprietary chemistry with digital innovation, these collaborations aim to deliver safer products that meet evolving regulatory standards.

Innovative pipeline management is another focal point for top competitors. Established players are diversifying their portfolios by acquiring or licensing novel analgesic candidates, thereby mitigating the impact of exclusivity expirations on legacy products. At the same time, several organizations are forging ties with contract manufacturing and research organizations to optimize operational flexibility and accelerate time to market. These arrangements enable rapid scale-up of production capacity without the need for significant capital expenditure.

Differentiation also extends to patient-engagement initiatives and payer relationships. Certain leaders have launched education programs and digital platforms designed to support clinicians and patients in safe opioid use, while negotiating value-based reimbursement agreements with insurers. By demonstrating improved clinical outcomes and reduced incidence of misuse, these firms aim to solidify formulary positioning and foster long-term trust among stakeholders, strengthening their competitive stance. Collectively, these strategic initiatives underscore the competitive imperative to integrate scientific innovation with robust commercial models in order to address both clinical and operational objectives effectively.

Actionable Recommendations Empowering Industry Leaders To Navigate the Opioid Narcotics Landscape Optimize Strategies Mitigate Risks And Drive Sustainable Growth

Industry leaders should prioritize investment in abuse-deterrent technologies, ensuring that next-generation formulations align with regulatory incentives and physician demand for enhanced safety. Establishing cross-functional teams that integrate clinical, regulatory, and commercial expertise will expedite development and streamline approval pathways. Concurrently, cultivating relationships with technology partners can infuse digital monitoring capabilities into product offerings, fostering improved adherence and real-world data collection.

Strengthening supply chain resilience is equally critical. Organizations are advised to diversify sourcing of key precursors, exploring domestic manufacturing partnerships to mitigate exposure to international tariff fluctuations. Scenario planning and stress testing of logistics networks can uncover vulnerabilities and support proactive risk mitigation. Transparent communication with suppliers and distributors will help maintain operational continuity and manage stakeholder expectations during periods of policy-induced disruption.

To enhance market access, companies should engage early with payers and healthcare providers, articulating value propositions that underscore clinical benefits and cost-savings associated with advanced formulations. Development of targeted educational initiatives for prescribers and patients can reduce barriers to adoption and foster responsible usage. Finally, continuous monitoring of emerging regulations and international policy trends will equip decision-makers to anticipate shifts and adapt strategies in a timely manner.

Rigorous Research Methodology Detailing Data Sources Analytical Framework And Validation Techniques Underpinning the Opioid Narcotics Market Assessment

This analysis draws upon a hybrid research approach that combines qualitative insights from key opinion leaders, in-depth interviews with regulatory officials, and primary feedback from clinicians across multiple regions. An extensive review of peer-reviewed journals, patent filings, and public health databases was conducted to establish a robust foundation of secondary information. These diverse inputs were synthesized to form the basis of the analytical framework.

Data triangulation was employed to reconcile discrepancies and ensure the accuracy of thematic findings. Quantitative metrics were cross-verified against industry reports and regulatory filings, while qualitative observations were validated through expert panel discussions. The methodological rigor was further strengthened by leveraging historical case studies of formulation approvals, supply chain adaptations, and tariff implementations, enabling a comprehensive view of trend emergence and impact.

To uphold credibility, a multi-tier validation process was instituted, encompassing internal peer reviews and external consultations with academic and clinical research institutions. Feedback loops were embedded throughout the project lifecycle to refine hypotheses and incorporate emerging data. This comprehensive methodological approach ensures that conclusions are drawn from a well-substantiated evidence base and remain defensible in high-stake decision processes.

Conclusive Insights Summarizing Critical Findings Strategic Implications And Future Considerations for Stakeholders in the Opioid Narcotics Domain

The convergence of regulatory tightening, technological innovation, and evolving patient expectations has redefined the opioid narcotics landscape. Key drivers include the imperative to develop safer formulations, adapt to new tariff regimes, and navigate diverse regional regulations. Segment analysis reveals that injectable and transdermal delivery methods demand tailored strategies, while branded and generic product dynamics shape long-term portfolio planning.

Regional insights underscore the need for differentiated market approaches, as stakeholder priorities vary across the Americas, Europe, Middle East and Africa, and Asia Pacific. Leading companies are advancing through strategic partnerships, supply chain diversification, and digital monitoring solutions, positioning themselves to capitalize on shifting clinical requirements. Actionable recommendations emphasize integrated cross-disciplinary collaboration, resilient sourcing models, and proactive payer engagement.

As the industry moves forward, continuous learning and agile adaptation will be paramount. Stakeholders must remain vigilant in tracking policy changes, embracing emerging technologies, and fostering patient-centric ecosystems. Ultimately, the insights offer a framework for anticipating future developments and navigating the complexities of opioid therapy management. By synthesizing the critical findings and strategic implications presented in this report, decision-makers can steer initiatives that balance therapeutic efficacy with safety, securing a sustainable path in the complex domain of opioid narcotics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Injectable
    • Nasal
    • Oral
    • Rectal
    • Transdermal
  • Product Type
    • Branded
    • Generic
  • Molecule Type
    • Fentanyl
    • Hydrocodone
    • Morphine
    • Oxycodone
  • Formulation Type
    • Extended Release
    • Immediate Release
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Ambulatory Care
    • Home Healthcare
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Johnson & Johnson
  • Purdue Pharma L.P.
  • Mallinckrodt plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Endo International plc
  • AbbVie Inc.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Sandoz International GmbH

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of abuse-deterrent formulations to curb opioid misuse while maintaining analgesic efficacy
5.2. Impact of increasing regulatory scrutiny on prescription opioid supply chain compliance costs
5.3. Growth of telemedicine prescriptions for chronic pain management and associated opioid consumption trends
5.4. Rising adoption of non-opioid pain management guidelines driving demand for alternative therapeutics
5.5. Effect of evolving Medicaid and Medicare reimbursement policies on high-dose opioid prescribing patterns
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Opioid Narcotics Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Nasal
8.4. Oral
8.5. Rectal
8.6. Transdermal
9. Opioid Narcotics Market, by Product Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Opioid Narcotics Market, by Molecule Type
10.1. Introduction
10.2. Fentanyl
10.3. Hydrocodone
10.4. Morphine
10.5. Oxycodone
11. Opioid Narcotics Market, by Formulation Type
11.1. Introduction
11.2. Extended Release
11.3. Immediate Release
12. Opioid Narcotics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Opioid Narcotics Market, by End User
13.1. Introduction
13.2. Ambulatory Care
13.3. Home Healthcare
13.4. Hospitals
14. Americas Opioid Narcotics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Opioid Narcotics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Opioid Narcotics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Johnson & Johnson
17.3.2. Purdue Pharma L.P.
17.3.3. Mallinckrodt plc
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.5. Viatris Inc.
17.3.6. Endo International plc
17.3.7. AbbVie Inc.
17.3.8. Hikma Pharmaceuticals PLC
17.3.9. Pfizer Inc.
17.3.10. Sandoz International GmbH
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. OPIOID NARCOTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL OPIOID NARCOTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. OPIOID NARCOTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. OPIOID NARCOTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. OPIOID NARCOTICS MARKET: RESEARCHAI
FIGURE 28. OPIOID NARCOTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. OPIOID NARCOTICS MARKET: RESEARCHCONTACTS
FIGURE 30. OPIOID NARCOTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. OPIOID NARCOTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPIOID NARCOTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL OPIOID NARCOTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HYDROCODONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY MORPHINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY OXYCODONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL OPIOID NARCOTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES OPIOID NARCOTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. CANADA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. CANADA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. CANADA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. CANADA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. CANADA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. MEXICO OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. MEXICO OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. MEXICO OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. MEXICO OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA OPIOID NARCOTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. GERMANY OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. GERMANY OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 166. GERMANY OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 167. GERMANY OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 168. GERMANY OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 169. GERMANY OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. GERMANY OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. GERMANY OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. GERMANY OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. FRANCE OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. FRANCE OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 178. FRANCE OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 179. FRANCE OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 180. FRANCE OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 181. FRANCE OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. FRANCE OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. FRANCE OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. FRANCE OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 193. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. RUSSIA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. ITALY OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. ITALY OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. ITALY OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 202. ITALY OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 203. ITALY OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 204. ITALY OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 205. ITALY OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. ITALY OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. ITALY OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. ITALY OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. SPAIN OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. SPAIN OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 214. SPAIN OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 215. SPAIN OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 216. SPAIN OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 217. SPAIN OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. SPAIN OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. SPAIN OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. SPAIN OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SAUDI ARABIA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SOUTH AFRICA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. DENMARK OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. DENMARK OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 262. DENMARK OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 263. DENMARK OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 264. DENMARK OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 265. DENMARK OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. DENMARK OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. DENMARK OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. DENMARK OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 277. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. NETHERLANDS OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. QATAR OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 284. QATAR OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 285. QATAR OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 286. QATAR OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 287. QATAR OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 288. QATAR OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 289. QATAR OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. QATAR OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. QATAR OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. QATAR OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. FINLAND OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. FINLAND OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. FINLAND OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 298. FINLAND OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 299. FINLAND OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 300. FINLAND OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 301. FINLAND OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. FINLAND OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. FINLAND OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. FINLAND OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 313. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SWEDEN OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 323. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 324. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 325. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. NIGERIA OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. EGYPT OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. EGYPT OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. EGYPT OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 332. EGYPT OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 333. EGYPT OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 334. EGYPT OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 335. EGYPT OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 336. EGYPT OPIOID NARCOTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 337. EGYPT OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 338. EGYPT OPIOID NARCOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 339. EGYPT OPIOID NARCOTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. EGYPT OPIOID NARCOTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. TURKEY OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 342. TURKEY OPIOID NARCOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 343. TURKEY OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 344. TURKEY OPIOID NARCOTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 345. TURKEY OPIOID NARCOTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 346. TURKEY OPIOID NA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Opioid Narcotics market report include:
  • Johnson & Johnson
  • Purdue Pharma L.P.
  • Mallinckrodt plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Endo International plc
  • AbbVie Inc.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Sandoz International GmbH